Commentary: Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery

Frontiers in Cardiovascular Medicine

Xiang-Dong Wu¹ 

关键词: tranexamic acid;    seizures;    thromboembolic complications;    coronary-artery surgery;    dose;   

DOI  :  10.3389/fcvm.2017.00045

学科分类：心脏病和心血管学

来源: Frontiers

【 摘 要 】

Tranexamic acid has been widely and routinely used as a prophylactic treatment to reduce the rate and severity of blood loss in many surgical disciplines, such as orthopedic and cardiac surgical procedures. However, whether such therapy would increase the risk of arterial or venous thrombotic events has long been uncertainty (1). Myles et al. performed the ATACAS trial published in NEJM, which underscored the benefits and potential risks of tranexamic acid in coronary-artery surgery (2). Tranexamic acid is associated with a lower risk of bleeding, without a higher risk of death or thrombotic complications, meanwhile, also higher postoperative seizures risk. This commentary aimed to discuss several issues related to tranexamic acid and the trial itself.

【 授权许可】

CC BY